Beyond Air: Doubling the Pipeline and Nearing the FDA Bell

Micro-cap medtech raises $30M, secures third GPO, and sharpens Gen II launch timeline to Q4

XAIR · Earnings Call · 2026-08-13

A Funded Runway to Gen II

Beyond Air reported another quarter of flat revenue but made the critical moves that set up its next leg: a fresh capital infusion, a third GPO win, and a more concrete FDA timeline. CEO Robert Goodman opened the call by highlighting the second generation LungFit system as the "most important near-term catalyst" and detailed that the company had "strengthened our balance sheet through an up to $30 million financing." That cash, CFO Daniel Moorhead later clarified, will fund the pilot builds and the subsequent commercial ramp: “It really is a lot for operations. So what we have going right now is we have the pilots, which are being built on the Gen II device, in the near term, and then upon FDA clearance, we'd be building a lot more devices and gaining commercial steam for 2027 and beyond.” — Daniel Moorhead, Chief Financial Officer · 2026-08-13 The financing provides the financial flexibility to execute the launch without depending on further equity. Beyond the balance sheet, the commercial progress was tangible. Goodman noted that “Pipelines actually doubled over the last five or six months” — Robert Goodman, Chief Executive Officer · 2026-08-13, and the company's third major group purchasing agreement (with Premier, Vizient, and a new partner) gives it access to a substantial portion of U.S. hospitals. This builds on the prior quarter's momentum, where Bob had said, “The most recent GPO that we signed on April 1st is up and running, and we're already doing evaluations.” — Robert Goodman, Chief Executive Officer · 2026-06-26 The expanded global distribution network now covers more than 40 countries, adding another layer of demand ahead of the domestic launch.

FDA Decision Now a Question of Q4, Not If

The biggest catalyst remains the PMA supplement for Gen II, submitted in June 2025. On the call, Goodman gave the clearest timeline yet, noting that they are in the audit phase and that a decision is likely in Q4:

We're now a month into Q3, so likely that would be a Q4 period. We're still in H2, and yes, if you want to try to figure out whether it be in Q3 or Q4, that's up to the FDA and how they're processing everything.
Robert Goodman, Chief Executive Officer · 2026-08-13

He emphasized that the FDA has been unusually responsive, and all required paperwork has been submitted, with the remaining work focused on final pilot builds and performance qualification. This is a sharpening from the prior call, where the company said it was "completely on track" but offered no granularity on timing — a direct evolution of the FDA approval narrative that has dominated the company's discourse for the past year.

The Financial Picture: Still Pre-Revenue Outside the Base

Revenue of $1.8M for the June quarter was flat sequentially, but management reaffirmed the calendar-2026 guidance of $8M and the 2027 range of $16-18M, which explicitly includes Gen II revenue. Total revenue is up more than 100% year over year, yet still just $2M at the latest quarter. The company recorded its third consecutive quarter of positive gross profit, with gross margin improving to 13% from 9% a year ago. Still, operating losses remain deep, and the balance sheet shows negative effective net cash of -$4M — a position the new financing is designed to bridge. The market has already voted with its feet: the stock is up over 500% in the last 90 days, even after a 33% pullback from its July peak. For a micro-cap with a market cap of roughly $5M, the FDA decision is effectively a binary event—and the company is now funded to reach it. The broader sector is also increasingly focused on commercial readiness, as seen in the sentiment across recent healthcare earnings, and Beyond Air is positioning itself to be at the center of that wave. This is a classic inflection story: a cash-constrained developer that has secured the capital and the commercial infrastructure to monetize an imminent approval. The risk remains execution, but the pieces are finally in place.